MGAT2-IN-1 is primarily used in research focused on metabolic disorders, particularly those related to lipid metabolism. It acts as an inhibitor of monoacylglycerol acyltransferase 2 (MGAT2), an enzyme involved in the synthesis of triglycerides. By inhibiting MGAT2, it helps reduce the absorption of dietary fats, making it a potential candidate for studying obesity and related conditions like type 2 diabetes and non-alcoholic fatty liver disease. Researchers also explore its role in understanding lipid homeostasis and developing therapeutic strategies for managing metabolic syndrome. Its application extends to preclinical studies aimed at evaluating its efficacy and safety in modulating lipid metabolism pathways.